GeneXpert MTB/RIF Assay: A Revolutionary Tool for Rapid Tuberculosis Diagnosis and Rifampicin Resistance Detection

Laskar N

Introduction

Tuberculosis (TB) remains a major global health challenge, with approximately 10 million new cases and 1.5 million deaths annually[1]. The rise of drug-resistant TB, particularly multidrug-resistant (MDR) TB, has compounded this issue, making accurate and timely diagnosis essential for effective treatment and controlling disease spread[1-3]. Traditional diagnostic methods, such as culture-based tests, may require 2 to 6 weeks for the growth of *Mycobacterium tuberculosis complex*, with conventional drug susceptibility testing adding up to 3 additional weeks. This prolonged timeframe often results in delayed treatment initiation, contributing to increase morbidity and mortality[4-6]. The GeneXpert MTB/RIF assay has emerged as a revolutionary molecular tool in TB diagnosis, providing rapid and precise detection of *Mycobacterium tuberculosis* and rifampicin resistance directly from patient sputum samples within two hours[3,7-9].

The GeneXpert MTB/RIF Assay

The GeneXpert MTB/RIF assay is based on real-time polymerase chain reaction (PCR) technology and offers an expedited approach to TB diagnosis compared to traditional methods[3,7-9]. It has transformed the diagnostic landscape by allowing both the detection of *M. tuberculosis* DNA and mutation in the rpoB gene that confer the identification of rifampicin resistance in a single test.

Methodology

o Sample Collection: Sputum samples are collected from patients suspected of TB infection.

o Sample Preparation: Sample reagent is added to the sputum sample in 2:1 ratio and mixed well and incubated at room temperature for 10 minutes. Two milliliters (ml) of processed sample is transferred to the Xpert MTB/RIF cartridge.

o Cartridge loading: The Cartridge is loaded into the GeneXpert instrument

o Analysis: The instrument automatically performs DNA extraction, amplification and detection of *M. tuberculosis* and rifampicin resistance within 1 hour 50 minutes and it provides a printable test result.

Figure1: *GeneXpert MTB/RIF Assay procedure[10]*

Clinical Impact

The GeneXpert MTB/RIF assay has revolutionized TB diagnosis and drug resistance testing by providing rapid and reliable results. Its immediate clinical implications include:

Address of Correspondence: Dr. Nourjahan Laskar, MBBS, M. Phil, Associate Professor, Department of Microbiology, IMC

o Early Treatment Initiation: Prompt diagnosis enables rapid initiation of appropriate therapy, reducing disease progression and minimizing transmission

o Drug Resistance Identification: Rifampicin resistance detection allows clinicians to tailor treatment strategies, reducing the risk of developing MDR TB

o Improved Outcomes: Timely diagnosis and appropriate treatment have been shown to significantly reduce the morbidity and mortality associated with TB

o Enhanced TB Control Programs: The assay's ability to detect rifampicin resistance supports better surveillance, facilitating targeted public health interventions

Discussion

The GeneXpert MTB/RIF assay has proven to be an invaluable tool for the rapid diagnosis of TB and the detection of drug resistance, particularly in resource-limited settings[4,11]. The high detection rate reinforces its importance in clinical practice[5,12,13]. However, the noted prevalence of rifampicin resistance highlights the need for continuous surveillance of drug resistance patterns to inform treatment guidelines[2,3,14]. While the assay offers excellent sensitivity and specificity, the potential for false negatives should be taken into account, particularly in cases where clinical suspicion remains high despite negative test results[2,3,9,15]. Future research should focus on addressing the causes of these false negatives and refining diagnostic accuracy.

Conclusion

The GeneXpert MTB/RIF assay represents a critical advancement in the fight against TB, offering a rapid, sensitive, and specific diagnostic tool for both *M. tuberculosis* and rifampicin resistance. Its ability to deliver results in under two hours makes it particularly useful in settings where TB is prevalent, and timely intervention is crucial. However, despite its significant advantages, careful attention must be given to the limitations, such as the potential for false negatives. With appropriate quality control measures and further research, the assay holds great promise for improving TB management globally.

References

1. World Health Organization. Global Tuberculosis Report 2023. Geneva: WHO; 2023.

2. Centers for Disease Control and Prevention. Traditional TB diagnostic methods. CDC; 2021.

3. World Health Organization. WHO Endorses New Rapid TB Diagnostic Test. WHO; 2010.

4. Nicol MP, Workman L, Isaacs W, Munro J, Black F, Eley B, Boehme CC, Zemanay W, Zar HJ. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis. 2011 Nov;11(11):819-24. doi: 10.1016/S1473-3099(11)70167-0.

5. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014 Jan 21; 2014(1): CD009593. doi: 10.1002/14651858.CD009593.pub3.

6. Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, Banada PP, Deshpande S, Shenai S, Gall A, Glass J, Krieswirth B, Schumacher SG, Nabeta P, Tukvadze N, Rodrigues C, Skrahina A, Tagliani E, Cirillo DM, Davidow A, Denkinger CM, Persing D, Kwiatkowski R, Jones M, Alland D. The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing. mBio. 2017 Aug 29;8(4):e00812-17. doi: 10.1128/mBio.00812-17

7. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A. Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medicine. 2010 Sep 9;363(11):1005-15. DOI: 10.1056/NEJMoa0907847

8. Zeka AN, Tasbakan S, Cavusoglu C2011.Evaluation of the GeneXpert MTB/RIF Assay for Rapid Diagnosis of Tuberculosis and Detection of Rifampin Resistance in Pulmonary and Extrapulmonary Specimens. Journal Of Clinical Microbiology, 2011 Dec; 49(12): 4138–4141. doi:10.1128/JCM.05434-11

9. World Health Organization. Xpert MTB/RIF implementation manual. Geneva: WHO; 2014.

10. Shenai R. WHO Recommended Tools to Improve Diagnosis of Active and Drug Resistant Tuberculosis. Acta Medica International 2015 Jul – Dec; 2(2): 118-129.

11. Cox HS, Daniels JF, Muller O, Nicol MP, Cox V, van Cutsem G, Moyo S, De Azevedo V, Hughes J. Impact of Decentralized Care and the Xpert MTB/RIF Test on Rifampicin-Resistant Tuberculosis Treatment Initiation in Khayelitsha, South Africa. Open Forum Infect Dis. 2015 Feb 26; 2(1): ofv014. doi: 10.1093/ofid/ofv014.

12. Masenga SK, Mubila H, Hamooya BM. Rifampicin resistance in mycobacterium tuberculosis patients using GeneXpert at Livingstone Central Hospital for the year 2015: a cross sectional explorative study. BMC Infect Dis. 2017 Sep 22;17(1):640. doi: 10.1186/s12879-017-2750-9.

13. Stevens WS, Scott L, Noble L, Gous N, Dheda K. Impact of the GeneXpert MTB/RIF Technology on Tuberculosis Control. Microbiol Spectr. 2017 Jan; 5(1): 10.1128/ microbiolspec.tbtb2-0040-2016. doi: 10.1128/microbiolspec

14. Sen S. Tuberculosis diagnosis in resource-limited settings. Med J Armed Forces India. 2018 Jul; 74(3): 211-212. doi: 10.1016/j.mjafi.2018.06.003. Epub 2018 Jul 30.

15. Pandey P, Pant ND, Rijal KR, Shrestha B, Kattel S, et al. Diagnostic Accuracy of GeneXpert MTB/RIF Assay in Comparison to Conventional Drug Susceptibility Testing Method for the Diagnosis of Multidrug-Resistant Tuberculosis. PLOS ONE 2017; 12(1): e0169798. https://doi.org/10.1371/journal.pone.0169798.